HHS commits to IP transparency following watchdog’s criticism

The US Department of Health and Human Services (HHS) will reveal more information regarding its licensing of IP to private companies for drug development, it has confirmed in a letter to a congressional watchdog.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Sanofi partners with HHS to work on COVID-19 vaccine

19 February 2020 Sanofi’s vaccine unit has united with the US Department of Health and Human Services to develop a vaccine for the COVID-19 virus, which has so far killed more than 2,000 people worldwide.

Big Pharma

J&J, HHS sign expanded deal to find COVID-19 vaccine

14 February 2020 Johnson & Johnson unit Janssen has expanded an existing R&D agreement with the US Department of Health and Human Services (HHS) as part of efforts to speed up the development of an investigational vaccine for the novel coronavirus COVID-19.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

HHS commits to IP transparency following watchdog’s criticism

More on this story

Editor's picks

Editor's picks

More features